MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. filed a Form 4 reporting that one of its directors acquired additional common shares through an automatic dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director was credited with 166 shares of MetLife common stock at a price of $77.82 per share, described as imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owned 22,923 MetLife common shares in direct form.
MetLife, Inc. reported a small insider share acquisition by one of its directors. On 12/09/2025, the director acquired 34 shares of MetLife common stock at $77.82 per share, increasing the director’s beneficial ownership to 9,082 shares, held directly.
The transaction reflects imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Under this plan, directors can defer receipt of shares that have become payable, with dividends on those deferred shares reinvested in additional deferred share units.
MetLife, Inc. filed a current report to disclose that, on December 1, 2025, it completed its previously announced transaction with Talcott Resolution Life Insurance Company to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves. This means a large block of MetLife’s variable annuity risk has been transferred to Talcott through a reinsurance arrangement.
The completion of this transaction is communicated under a Regulation FD disclosure, with further details provided in a related news release that is attached as an exhibit and incorporated by reference.
MetLife-related accounts have filed a Form 144 to sell a small block of common stock. The notice covers a proposed sale of 335 shares of MetLife common stock through Wells Fargo, with an aggregate market value of 25,647.6, on the New York Stock Exchange on or about 12/01/2025. The issuer had 658,891,656 shares outstanding at the time referenced.
The seller acquired the 335 shares in a cash purchase from Goldman Sachs on 05/29/2015, with payment made on 06/03/2015. Over the past three months, several MetLife-related accounts, including Separate Account II, Separate Account SPI, Separate Account 149, the MetLife 401k Plan Trust-Large Cap Equity Index, and the MetLife 401k Plan Russell 1000 Value, sold additional blocks of MetLife common stock in multiple transactions, with gross proceeds for individual trades ranging from 1,345.72 to 27,282.69.
MetLife (MET) has a Form 144 notice covering a planned sale of common stock for the account of a reporting holder. The filing states that the holder intends to sell 30 shares of common stock through Barclays on the NYSE on or about 11/20/2025, with an aggregate market value of 2242.8. These 30 shares were acquired on 10/11/2021 via a purchase from Citigroup Global Markets, paid in cash on 10/13/2021.
The notice also lists other recent sales of the issuer’s common stock over the past three months by MetLife-related accounts, including 333 shares sold by MetLife 401k Plan Trust-Large Cap Equity Index on 10/01/2025 for gross proceeds of 27282.69 and 196 shares sold by MetLife 401k Plan Russell 1000 Value on 10/29/2025 for 15350.72. The signer represents that they are not aware of undisclosed material adverse information about the issuer.
MetLife, Inc. declared quarterly dividends on its preferred stock, providing cash income to holders of its Series A, Series E and Series F securities. The Series A floating rate non-cumulative preferred stock will pay a quarterly dividend of $0.33489390 per share. The 5.625% non-cumulative preferred stock, Series E, will pay $351.5625 per share, or $0.3515625 per depositary share, each representing a 1/1,000th interest in a share. The 4.75% non-cumulative preferred stock, Series F, will pay $296.875 per share, or $0.296875 per depositary share, each representing a 1/1,000th interest in a share.
MetLife, Inc. filed a Form 13F Combination Report reporting holdings managed by its investment subsidiaries. The report lists 6 securities entries with a total reported market value of $11,126,208. The filing is signed by John McCallion on 11-10-2025.
MetLife, Inc. reported a change in beneficial ownership. The Board of Directors, as an entity, filed an amended Schedule 13D noting beneficial ownership of 106,549,803 shares of common stock, representing 16.17% of the class as of October 31, 2025. The Board has shared voting power over 106,549,803 shares and no sole voting or dispositive power.
The shares are held by the MetLife Policyholder Trust, originally issued 494,466,664 shares in 2000 under the demutualization plan. The Trustee votes per Board recommendations on most matters; on specified Beneficiary Consent Matters, votes are cast in proportion to beneficiary instructions. Since July 31, 2025, Trust holdings decreased from 108,242,821 to 106,549,803 due to beneficiary transactions and withdrawals under the Plan and Trust Agreement. Beneficiaries have rights to dividends and sale proceeds on their allocated shares.
MetLife, Inc. reports mixed results for the quarter and nine months ended September 30, 2025. Total revenues for the quarter were $17.4 billion, down from $18.4 billion a year earlier, and net income fell to $902 million from $1.34 billion. Diluted EPS for common shareholders declined to $1.22 from $1.81.
For the first nine months of 2025, revenues were $53.3 billion versus $52.3 billion, but net income decreased to $2.59 billion from $3.17 billion, reflecting weaker investment and derivative results. By contrast, consolidated adjusted earnings rose to $1.65 billion in the quarter from $1.44 billion, with strong contributions from Asia and Group Benefits.
Operating cash flow remained robust at $10.0 billion for the nine months. The company continued returning capital, repurchasing $2.42 billion of common stock and redeeming $988 million of preferred stock, while total assets grew to $719.7 billion and equity to $29.2 billion.
MetLife, Inc. furnished investor materials for the quarter ended September 30, 2025. The company provided an Earnings Release (Exhibit 99.1), a Quarterly Financial Supplement (Exhibit 99.2), a Total AUM Fact Sheet (Exhibit 99.3), and Supplemental Slides (Exhibit 99.4). These materials are furnished, not filed, and summarize quarterly results and assets under management.